Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Summary

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.

Eligibility

Inclusion Criteria:

Exposed cohort

1. Currently or recently (within 1 year of pregnancy outcome) pregnant
2. Diagnosis of moderate/severe SLE
3. Consent to participate
4. Authorization for their HCP(s) to provide data to the registry
5. Exposure to at least 1 dose of anifrolumab at any time during pregnancy

Unexposed cohort

1. Currently or recently pregnant
2. Diagnosis of moderate/severe SLE
3. Consent to participate
4. Authorization for their HCP(s) to provide data to the registry
5. Exposure to other products for the treatment of moderate/severe SLE

Exclusion Criteria:

Exposed cohort

1. Occurrence of pregnancy outcome prior to first contact (for enrollment) with the Virtual Research Coordination Center (retrospectively enrolled)
2. Exposure to known teratogens and/or investigational medications during pregnancy

Unexposed cohort

1. Occurrence of pregnancy outcome prior to first contact with the Virtual Research Coordination Center (retrospectively enrolled)
2. Exposure to known teratogens and/or investigational medications during pregnancy

Conditions2

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. — AstraZeneca
• Anifrolumab Malignancy and Serious Infections Study — AstraZeneca
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus — AstraZeneca
• The Anifrolumab PRIM Program — AstraZeneca
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — AstraZeneca
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — AstraZeneca
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — AstraZeneca

Browse More Trials